EUPATI Patient Expert Training Programme 2024 / 2025

UPDATE

Part of Cohort 8 I finished my first five compulsory modules yesterday. Interesting but challenging even for an English speaker! The main hurdle for me was  statistics in the last module!

‍

• Introduction to medecines R&D (6 courses)
  • Process of Medicines  Discovery and Development
  • Role of Patients and  Patient Organisations in Medicines R&D
  • Role of  Translational Research in Medicines R&D
  • Concepts of  Evidence-Based Medicines and Outcomes Research
  • Predisposing Factors  and Underlying Mechanisms of Disease
  • Types of Medicines  and Their Mode of Action and Use‍
• Non Clinical Development (3 courses)
  • Role of Pharmacogenetics /  Pharmacogenomics in the Development of Medicines
  • Requirements for Non-clinical  Studies and the Purpose and Relevance of Animal Testing
  • Development of Medicines  Substance and Final Medicines Product‍
• Clinical Development   (7 courses)‍
  • Interpretation and  Dissemination of Results ‍
  • Documentation &  Management ‍
  • Early Clinical Development‍‍
  • ‍Clinical Trials and Trial  Management ‍
  • Trial Participants' Rights  & Obligations
  • ‍Ethics
  • ‍Statistics
• Regulatory affairs (5 courses)‍
  • Introduction to Regulatory  Affairs‍
  • Epidemiology and  Pharmacoepidemiology‍
  • Pharmacovigilance - Risk  management‍
  • ‍Product information and  information to the public
  • R‍egulatory procedures-  Marketing-Authorisations and their lifecycle management ‍
• Health Technology Assessment (HTA) (6 courses)‍
  • Introduction to Health  Technology Assessment (HTA)
  • HTA Bodies and Principles
  • ‍HTA and Evaluation Methods:  Quantitative
  • ‍HTA and Evaluation Methods:  Qualitative
  • ‍Patient Involvement in HTA‍
  • EU Health Technology Assessment  Regulation (HTA)

Next step 4 days online training, the first two of which I'll be in Washington D.C. so early 5 a.m. start